



HERVÉ JACQUIAU, J.D., Ph.D., M.Sc., D.E.A. ASSOCIATE



Hahn Loeser & Parks LLP
200 West Madison Street, Suite 2700
Chicago, Illinois 60606

p 312.637.3022 **f** 312.637.3001
e hjacquiau@hahnlaw.com

hahnlaw.com

Dr. Hervé Jacquiau focuses his legal practice in the areas of Intellectual Property, Business Development and Research & Development. Formerly a patent agent and technical advisor with the firm, Hervé has years of experience involving patent prosecution and litigation.

His background covers a variety of technologies, particularly biotechnology (e.g. biofuels, fermentation processes); chemical engineering, molecular pharmacology and biochemistry (e.g. pharmaceuticals, biosimilars); cell biology, genetics and microbiology (e.g. biosensors, medical research, oncology); food and biology industries (e.g. wine, antibiotics and antibody production).

Before receiving his law degree, Hervé received his Ph.D. from the University of Cambridge after investigating the genetic and biochemical features responsible for the biodegradation of toxic pollutants. He developed novel genetic tools to develop biosensors and became co-inventor (U.S. Patent No. 6,849,442). His work contributed to the creation of a biotechnology company that specializes in developing biosensors for the detection and removal of environmental contaminants.

As a postdoctoral research associate at St. Jude Children's Research Hospital, Hervé investigated various mechanisms that regulate cellular sensitivity or resistance to anti-cancer agents. He investigated DNA rearrangements and cell-cycle regulation and highlighted the role of various mechanisms of protein degradation in modulating cellular response to enzyme inhibitors that are commonly used in the treatment of childhood cancer.

Hervé previously worked at the Lankenau Institute for Medical Research (LIMR), where he conducted translational research and developed antibodies to be used in cancer diagnostics or research tools. At the institute, Hervé evaluated scientific innovations and business proposals to develop IP strategies and to expand LIMR's biotechnology incubators. He subsequently became a business and scientific funding associate in the Department of Business Development.



HERVÉ JACQUIAU, J.D., Ph.D., M.Sc., D.E.A. ASSOCIATE

Hervé contributed to the creation of a novel drug screening facility for drug target validation and drug discovery, as well as a center for the production of human antibodies to be used as medical diagnostics or as novel therapeutics. He collaborated with surgeons and clinicians to develop protocols for clinical trials. Hervé also wrote proposals to attract funding and to promote scientific collaborations.

Earlier in his career, Hervé earned a master of science degree in bioreactor systems and biotechnology. As an undergraduate, he studied biological sciences, as well as the food and biological industries.

Publications & Speaking Engagements

- Co-author, "Defects in SUMO conjugation and desumoylation alter cell sensitivity to DNA topoisomerase I-induced DNA damage," *Journal of Biological Chemistry*, Volume 280, Pages 23566-23575, 2005.
- Speaker, American Association for Cancer Research annual meeting, Orlando, Fla., and Anaheim, Calif., 2004-2005.
- Co-author, "The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons," *Journal of Biological Chemistry*, Volume 279, Pages 21271-21281, 2004.
- Co-author, "SUMO conjugation and proteolysis regulate cell sensitivity to Top I poisons," *European Journal of Cancer*, Volume 2, Page 153, 2004.
- Co-author, "The DNA replication licensing factor TAH11 (CDT1) functions to protect cells from Camptothecin and replication fork arrest," *Proceedings of the American Association for Cancer Research*, Volume 45, Page 1243, 2004.
- Co-author, "DNA Topoisomerase in Cancer Therapy-Present & Future," Chapter 5, Andoh T. ed., *Kluwer Academic*, New York, Pages 89-108, 2003.
- Co-author, "Alterations in the SUMO-conjugating enzyme UBC9 distinguish enzyme functions essential for cell viability and responses to DNA damage," *Proceedings of the AACR*, Volume 44, Pages 360-361, 2003.
- Co-author, "Ubiquitin-mediated proteolysis and cell sensitivity to Camptothecin," *Proceedings of the American Association for Cancer Research*, Volume 43, Page 248, 2002.
- Speaker, Symposium, "Molecular Targets and Cancer Therapeutics," National Cancer Institute, Geneva, Switzerland, 2004.
- Speaker, Conference on DNA topoisomerases in therapy, New York School of Medicine, New York, N.Y., 2001.

Professional History

- Associate, Hahn Loeser & Parks LLP, 2018-present; Patent Agent & Technical Advisor 2015-18.
- Technical Advisor & Patent Agent, Husch Blackwell LLP, 2009-15.
- Business and Scientific Funding Associate, Lankenau Institute for Medical Research, Department of Business Development, 2008-09.
- Junior Faculty Member: Scientist, Lankenau Institute for Medical Research, 2006-07.
- Postdoctoral Research Associate, St. Jude Children's Research Hospital, Department of Molecular Pharmacology, 2000-06.

Admissions

- State of Illinois, 2018.
- State of Florida, 2019.
- U.S. District Court for the Northern District of Illinois, 2019.
- U.S. Patent and Trademark Office (Registration Number: 64976).

Education

- Chicago Kent College of Law, J.D. 2017.
 - Honors & Activities: CALI Excellence for the Future Award in Client Counseling, Recipient; CALI Excellence for the Future Award in Mergers & Acquisitions, Recipient; CALI Excellence for the Future Award in Legal Writing III, Recipient; Certificate of Distinction in Strategies in Intellectual Property Law, Recipient; Dean's Honor List (2013-2017). Elective courses: Mergers & Acquisitions; Business Valuation & Financial Statement Analysis; Business Organizations; Corporate Finance; Hedge Funds; Securities Regulation; Personal Income Tax; Strategies in Intellectual Property Law; Patent Law; Copyright Law; Trademarks & Unfair Competition; Food & Drug Law; Client Counseling; Negotiations; Remedies; Regulation of New Technologies; Trial Advocacy. Mandatory courses: Agency and Partnership; Corporations; Contracts; Criminal Law; Civil Procedure; Evidence; Property; Torts; Constitutional Law; Legislation; Legal Writing; Professional Responsibility.
- University of Cambridge, Ph.D., Genetics, 2000.
 - Honors & Activities: Marie Curie Research Fellowship, Recipient; Industrial Case Studentship, Biotechnology & Biological Sciences Research Council, Recipient.
- University of Manchester Institute of Science and Technology, M.Sc., Bioreactor Systems, 1995.
 - Honors & Activities: Goodwill Ambassadorial Scholarship of the Rotary International, Recipient.



HERVÉ JACQUIAU, J.D., Ph.D., M.Sc., D.E.A. ASSOCIATE

- Institut National des Sciences Appliquées de Toulouse, D.E.A., Biotechnology, 1995.
- Manchester Metropolitan University, B.Sc.(Hons), Biological Sciences, 1994.
- Paris XII University, D.U.E.T., Applied Biology, 1993.
- Paris XII University, University Institute of Technology, D.U.T., Food and Biological Industries, 1992.

Memberships & Affiliations

- American Bar Association, Member.
- Chicago Bar Association, Member.
- Phi Alpha Delta Law Fraternity, Member.
- Marie Curie European Research Fellowship Association, Member.
- University of Cambridge Alumni Association, Member.
- University of Manchester/UMIST Alumni Association, Member.